NorthWest Biotherapeutics Inc (NWBO)

[Astavakra]

This is a important point to make because any ascribed benefit from DCVax-L treatment must come from observations that this benefit is over and above any benefit that an additional treatment has been ascribed in a similar setting as that in which it has previously been used for as a monotherapy.
Doc logic

Your point adds even more weight to the highly anticipated, peer reviewed, article that we're told will contain input from the various investigators on site, on the front lines, who are qualified to observe whether DCVax L is over and above other mono-therapies prescribed in their institutions under their, or a colleague's supervision. I am so eager to see this article published. I hope that it's in an irrefutably significant journal and that there is little to no ambiguity or opinion. Just hard facts and quality of life observations. Every days brings us closer to something....